Karen L. Reckamp, MD, MS

Articles

Dr Reckamp on Emerging EGFR TKIs in EGFR Exon 20 Insertion+ NSCLC

August 21st 2024

Karen L. Reckamp, MD, MS, discusses emerging EGFR TKIs in EGFR Exon 20–Mutated NSCLC.

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

July 26th 2024

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

August 9th 2023

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Dr Reckamp on the Effect of Adjuvant Atezolizumab on Patient Outcomes in Resectable Stage IB-IIIA NSCLC

April 21st 2023

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLC

February 28th 2020

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer

June 1st 2017

This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.